- Home
- BTAI vs YCBD Comparison
BTAI vs YCBD Comparison
Compare BTAI & YCBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- YCBD
- Stock Information
- Founded
- BTAI 2017
- YCBD 2015
- Country
- BTAI United States
- YCBD United States
- Employees
- BTAI N/A
- YCBD N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- YCBD Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- YCBD Health Care
- Exchange
- BTAI Nasdaq
- YCBD Nasdaq
- Market Cap
- BTAI 8.3M
- YCBD 7.8M
- IPO Year
- BTAI 2018
- YCBD N/A
- Fundamental
- Price
- BTAI $5.48
- YCBD $0.76
- Analyst Decision
- BTAI Strong Buy
- YCBD Strong Buy
- Analyst Count
- BTAI 4
- YCBD 1
- Target Price
- BTAI $40.00
- YCBD $3.00
- AVG Volume (30 Days)
- BTAI 22.4M
- YCBD 104.3K
- Earning Date
- BTAI 08-12-2025
- YCBD 08-14-2025
- Dividend Yield
- BTAI N/A
- YCBD N/A
- EPS Growth
- BTAI N/A
- YCBD N/A
- EPS
- BTAI N/A
- YCBD N/A
- Revenue
- BTAI $868,000.00
- YCBD $19,026,064.00
- Revenue This Year
- BTAI N/A
- YCBD $7.67
- Revenue Next Year
- BTAI $328.13
- YCBD $10.00
- P/E Ratio
- BTAI N/A
- YCBD N/A
- Revenue Growth
- BTAI N/A
- YCBD N/A
- 52 Week Low
- BTAI $1.17
- YCBD $0.76
- 52 Week High
- BTAI $13.36
- YCBD $6.54
- Technical
- Relative Strength Index (RSI)
- BTAI 67.45
- YCBD 35.38
- Support Level
- BTAI $1.30
- YCBD $0.81
- Resistance Level
- BTAI $8.08
- YCBD $0.96
- Average True Range (ATR)
- BTAI 1.23
- YCBD 0.08
- MACD
- BTAI 0.33
- YCBD -0.01
- Stochastic Oscillator
- BTAI 61.65
- YCBD 0.00
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.